Excretion of SARS-CoV-2 RNA in feces has no prognostic benefit in the outcome of COVID-19: A clinical and immunological study

Authors

  • Božo Šušak Department of Infectious Diseases, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina; School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina https://orcid.org/0000-0002-5401-9001
  • Monika Dalmatin-Dragišić Department of Infectious Diseases, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina https://orcid.org/0009-0000-4827-4789
  • Luka Laura Faculty of Pharmacy, University of Mostar, Mostar, Bosnia and Herzegovina https://orcid.org/0009-0001-4905-3299
  • Vinka Mikulić School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina; Department of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina https://orcid.org/0000-0001-8913-3018
  • Katarina Nakić School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina
  • Ivanka Mikulić School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina; Department of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina
  • Ilija Brizić Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia https://orcid.org/0000-0001-8839-7839
  • Jurica Arapović Department of Infectious Diseases, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina; School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina https://orcid.org/0000-0002-7674-6795
  • Maja Arapović School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina https://orcid.org/0000-0001-6043-3666

DOI:

https://doi.org/10.17305/bb.2024.10176

Keywords:

Coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 testing, immunoglobulin G, vaccination, viral load, feces, signs and symptoms, patient outcome

Abstract

This study explores the correlation between immunological and clinical characteristics in coronavirus disease 2019 (COVID-19) patients with detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in feces, analyzing data from 251 patients admitted to Mostar University Clinical Hospital (UCH) from December 2021 to January 2022. Methods involved reverse transcription quantitative polymerase chain reaction (RT-qPCR) from nasopharyngeal (NP) swabs and feces, alongside serological tests for anti-SARS-CoV-2 spike IgGs. Demographic and clinical data were collected through questionnaires and medical records. The data analyses were performed using SPSS statistical software. Death occurred in 53 patients (21.1%, P < 0.001), mostly in the elderly (47/53, 88.7%, P = 0.001) and immunocompromised (19/53, 35.8%, P = 0.05), particularly those developing acute respiratory insufficiency (ARI) (46/53, 86.8%, P = 0.004), and severe/critical disease (46/53, 86.8%, P = 0.002). Among the patients with positive anti-SARS-CoV-2 IgG antibodies (86/251, 34.3%, P < 0.001), 41 (47.7%) were vaccinated and 45 (52.3%) unvaccinated (P = 0.666), showing no significant differences in clinical outcomes or mortality. Unvaccinated patients with a negative antibody titer had a higher incidence of ARI (96/123, 78%, P = 0.029) and intensive care unit (ICU) admission (22/123, 17.9%, P = 0.026), than those with a positive antibody titer. Forty-seven (62.7%) patients, out of the 75 hospitalized who provided a feces sample, were positive for SARS-CoV-2 RNA (P = 0.028), without statistical differences between fecal SARS-CoV-2 positive and negative groups regarding vaccination status (15/47, 31.9%, P = 0.493), antibody status (18/47, 38.3%, P = 0.628), or death outcome (5/47, 10.6%, P = 0.706). In conclusion, unvaccinated hospitalized patients with a severe COVID-19 presentation and a negative anti-spike SARS-CoV-2 IgG titer had adverse outcomes more frequently. This suggests cautious consideration for the diagnostic use of fecal samples compared to NP swabs.

Citations

Downloads

Download data is not yet available.
SARS-CoV-2 viral load in feces does not have a prognostic benefit in outcome of COVID-19: Clinical and immunological study

Downloads

Published

10-02-2024

Issue

Section

Research article

Categories

How to Cite

1.
Excretion of SARS-CoV-2 RNA in feces has no prognostic benefit in the outcome of COVID-19: A clinical and immunological study. Biomol Biomed [Internet]. 2024 Feb. 10 [cited 2024 Sep. 14];24(4):1016-27. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/10176